Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs

J R Soc Interface. 2011 Aug 7;8(61):1114-27. doi: 10.1098/rsif.2010.0609. Epub 2011 Jan 12.

Abstract

The epidermal growth factor receptor (EGFR) is a major target for drugs in treating lung carcinoma. Mutations in the tyrosine kinase domain of EGFR commonly arise in human cancers, which can cause drug sensitivity or resistance by influencing the relative strengths of drug and ATP-binding. In this study, we investigate the binding affinities of two tyrosine kinase inhibitors--AEE788 and Gefitinib--to EGFR using molecular dynamics simulation. The interactions between these inhibitors and the EGFR kinase domain are analysed using multiple short (ensemble) simulations and the molecular mechanics/Poisson-Boltzmann solvent area (MM/PBSA) method. Here, we show that ensemble simulations correctly rank the binding affinities for these systems: we report the successful ranking of each drug binding to a variety of EGFR sequences and of the two drugs binding to a given sequence, using petascale computing resources, within a few days.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Computer Simulation*
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / enzymology*
  • Lung Neoplasms / genetics
  • Models, Molecular*
  • Mutation*
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism
  • Protein Kinase Inhibitors / chemistry*
  • Protein Structure, Tertiary
  • Purines / chemistry*
  • Quinazolines / chemistry*

Substances

  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Purines
  • Quinazolines
  • EGFR protein, human
  • ErbB Receptors
  • AEE 788
  • Gefitinib